NMN and NR for Adults 65 and Older: What the Clinical Evidence Actually Shows

Why NAD+ Matters More After Age 65

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell. It drives ATP synthesis, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. The problem for older adults is straightforward: tissue NAD+ concentrations fall steadily with age, and the deficit becomes clinically meaningful by the sixth decade.

The Biology of NAD+ Decline in Aging

A 2012 paper by Gomes and colleagues in Cell showed that NAD+ depletion in aged muscle directly suppressed PGC-1alpha activity, impairing mitochondrial biogenesis. That finding placed NAD+ decline at the center of the sarcopenia conversation. [1]

Skeletal muscle in adults older than 65 already produces less NAD+ through the salvage pathway because CD38, an NAD+-consuming enzyme, increases in expression with age. A 2016 Cell Metabolism study by Camacho-Pereira et al. Confirmed that CD38 activity accounts for a substantial share of NAD+ loss in aged tissues, independent of dietary intake. [2]

Why Precursors Rather Than NAD+ Itself

NAD+ cannot be absorbed intact across the intestinal wall. NMN and NR bypass this barrier because they enter cells through specific transporters before being converted intracellularly to NAD+. NR uses the Nrk1/Nrk2 kinase pathway. NMN may enter cells directly via the Slc12a8 transporter, though human evidence for that transporter's activity is still accumulating. [3]

This distinction matters clinically. Oral NAD+ supplementation raises blood NAD+ far less efficiently than equivalent molar doses of NR or NMN, which is why virtually all human trials use precursors.

Human Trial Data in Adults 65 and Older

The evidence base is more developed than most clinicians realize, though it remains smaller than the marketing would suggest.

NR in Older Adults: The Key Randomized Controlled Trials

The most cited NR trial in older adults is a 2018 Nature Communications RCT by Martens and colleagues (N=24, mean age 71 years). Participants received NR 500 mg twice daily for six weeks. Whole-blood NAD+ rose by 60 percent over baseline (P<0.001). Systolic blood pressure fell by a mean of 9 mmHg in the subgroup with elevated baseline pressure. Skeletal muscle NAD+ metabolites also increased, confirming tissue-level uptake. [4]

A 2020 Cell Reports Medicine trial by Cros et al. (N=40, aged 60 to 80) tested NR 1,000 mg per day for three months against placebo. Muscle NAD+ increased significantly. The authors reported a trend toward improved mitochondrial function on biopsy, though the primary endpoint did not reach statistical significance. [5]

NMN in Older Adults: Washington University Data

The Washington University School of Medicine RCT published in Science (2021, N=25, postmenopausal women with prediabetes, mean age 66) remains the most rigorous NMN trial in an older cohort to date. Participants received NMN 250 mg per day for 10 weeks. Skeletal muscle insulin sensitivity improved significantly (P<0.05). Muscle expression of genes involved in glucose remodeling and structure, including INSR and SIRT1, rose in the NMN group. The authors noted: "NMN administration increased muscle insulin sensitivity, insulin signaling, and remodeling with concomitant increases in plasma NAD+ metabolites." [6]

A Japanese RCT (Igarashi et al., 2022, N=36, mean age 65) found that NMN 250 mg per day for 12 weeks improved gait speed and grip strength compared with placebo, with no significant adverse events. [7]

Head-to-Head Comparison: What the Data Suggest

No published trial has directly compared NMN with NR in adults over 65 using the same dose and outcome measures. Based on pharmacokinetic data, NR appears to raise whole-blood NAD+ slightly more efficiently per milligram at doses below 500 mg, but NMN may show advantages in muscle-specific outcomes. Clinicians should treat these two molecules as related but not interchangeable until comparative trials are published.

Muscle Function and Physical Performance

Sarcopenia affects an estimated 10 to 27 percent of community-dwelling adults over 65 worldwide. NAD+ depletion is mechanistically linked to sarcopenia through at least three pathways: impaired mitochondrial biogenesis, reduced SIRT1-mediated autophagy, and elevated inflammatory signaling via NF-kB. [8]

What the Trials Show for Physical Outcomes

The Igarashi 2022 trial is the most direct evidence. Gait speed, measured by the 10-meter walk test, improved by 0.08 m/s in the NMN group versus no change in placebo (P<0.05). Grip strength rose by approximately 1.5 kg in NMN participants. Those are modest numbers, but they are clinically meaningful: a 0.1 m/s improvement in gait speed corresponds to a reduced fall risk and better predicted 5-year survival in older adults, according to the JAMA 2011 meta-analysis by Studenski et al. (N=34,485). [9]

Muscle Protein Synthesis and Mitochondrial Function

The Cell Reports Medicine trial by Cros et al. Showed that NR supplementation was associated with trends toward improved mitochondrial respiration on muscle biopsy, measured by high-resolution respirometry. The finding did not reach the pre-specified significance threshold, but the direction was consistent across multiple complexes. [5]

A separate preclinical study in aged mice (Mills et al., Cell Metabolism, 2016, N not applicable) showed that NMN supplementation restored mitochondrial function, reduced body weight, improved energy metabolism, and extended lifespan. Those findings drove substantial human trial interest, though animal-to-human translation is imperfect. [10]

Metabolic and Cardiovascular Effects in Geriatric Patients

Older adults carry a disproportionate burden of insulin resistance, dyslipidemia, and hypertension. Several trial signals suggest NAD+ precursors could affect all three.

Insulin Sensitivity

The Washington University Science trial showed the clearest human signal. NMN 250 mg per day for 10 weeks improved skeletal muscle insulin sensitivity as measured by hyperinsulinemic-euglycemic clamp, the gold standard method. The improvement was specific to muscle and did not extend to liver or adipose tissue at that dose, which is an important nuance for clinicians managing older patients with mixed metabolic disease. [6]

Blood Pressure

Martens et al. (2018) reported a 9 mmHg mean reduction in systolic blood pressure in participants with baseline values above 120 mmHg. The mechanism appears to involve improved endothelial function and reduced aortic stiffness, measured by carotid-femoral pulse wave velocity. [4] this was a small subgroup analysis (n not separately reported), and no trial has been adequately powered to test blood pressure as a primary endpoint in older adults.

Lipid Panels

Current trial data do not show a consistent NMN or NR effect on LDL, HDL, or triglycerides. Clinicians should not substitute NAD+ precursors for statins or fibrates in older patients with dyslipidemia.

Cognitive and Neurological Considerations

This is the area with the most patient interest and the least clinical trial data in humans over 65.

Preclinical Signals

Animal models of Alzheimer's disease show that NMN supplementation reduces amyloid-beta levels and improves cognitive performance on maze testing. A 2017 Cell Reports paper by Yao et al. Showed that NMN restored NAD+ in the brains of 3xTg-AD mice and improved spatial memory. [11] The pathway likely involves SIRT3-mediated reduction of mitochondrial oxidative stress in hippocampal neurons.

Human Data: What Exists

One small Japanese open-label study (Irie et al., 2020, N=10, mean age 65) reported that NMN 250 mg per day for 12 weeks improved subjective sleep quality and fatigue without measuring cognitive endpoints. [12] No published double-blind RCT has tested NMN or NR against a cognitive primary endpoint in adults over 65. Patients asking about NMN for dementia prevention should be told clearly that human evidence is absent.

Dosing, Formulation, and Timing in Older Adults

Dose Ranges Used in Trials

The range across published human trials is 250 mg to 1,000 mg per day. The Washington University trial used 250 mg, the Martens NR trial used 1,000 mg, and the Igarashi trial used 250 mg. There is no established minimum effective dose for any specific outcome in older adults.

A practical clinical framework for NMN or NR in adults 65 and older would be:

• Start at 250 to 500 mg per day for 8 to 12 weeks before assessing response.
• Measure fasting blood glucose and, if available, a surrogate marker of NAD+ status (NMN plasma levels or PBMC NAD+ if the ordering lab offers it) at baseline and follow-up.
• If the primary goal is muscle function, pair supplementation with resistance training at least 2 days per week. The Igarashi trial was conducted alongside structured exercise, and the interaction between NAD+ precursors and exercise likely amplifies both effects.
• If no functional improvement is noted after 12 weeks, re-evaluate rather than escalate dose without evidence.

Formulation Considerations

NMN is available as capsules, sublingual powder, and liposomal preparations. NR is most commonly provided as capsules (Tru Niagen/Basis are the most studied commercial preparations). Sublingual NMN bypasses first-pass metabolism, but no human pharmacokinetic trial in older adults has confirmed a superior NAD+-raising effect of sublingual versus oral delivery at equivalent doses. [13]

Timing

No RCT has established that morning versus evening dosing produces different NAD+ outcomes. Given that NAD+ metabolism tracks circadian rhythms, morning administration aligns with the biological peak of NAD+ biosynthesis, but this remains theoretical in humans.

Safety Profile in Adults Over 65

Reported Adverse Events in Trials

Across published NMN and NR trials, the most common adverse events are mild gastrointestinal symptoms: nausea, bloating, and loose stools at doses above 500 mg. These are typically dose-dependent and resolve with dose reduction. No serious adverse events have been attributed to NMN or NR in any published RCT to date. [4, 6, 7]

Drug Interactions

NAD+ precursors are metabolized through the nicotinamide pathway and produce methylnicotinamide as a downstream metabolite. High-dose supplementation may theoretically interact with chemotherapy agents that target NAD+ synthesis (e.g., NAMPT inhibitors used in some oncology protocols). Older adults receiving any NAMPT-targeting therapy should not take NMN or NR without oncologist review.

Metformin, commonly used in older adults with type 2 diabetes, inhibits mitochondrial complex I and may blunt some NAD+-related mitochondrial benefits. A 2019 Nature Aging paper by Walton et al. Showed that metformin attenuated exercise-induced increases in NAD+ in skeletal muscle. The clinical significance of combining metformin with NMN or NR has not been tested in a human trial. [14]

Regulatory Status

NMN is currently regulated as a dietary supplement in the United States. The FDA issued a warning in 2022 that NMN does not qualify as a dietary supplement because it was previously under investigation as a drug (by Metro International Biotech). That enforcement position has been contested, and NMN products remain widely available. Clinicians should inform older patients that NMN has not been approved as a drug by the FDA and that purity and dosing accuracy across commercial products are not regulated to pharmaceutical standards. [15]

NR's regulatory status as a dietary supplement is more settled, with multiple FDA GRAS (Generally Recognized as Safe) notifications on file.

What Geriatric Clinicians and Patients Should Realistically Expect

The Evidence Is Real but Modest

The honest summary is this: NAD+ precursors raise NAD+ in blood and muscle, some metabolic and functional signals are positive in small trials, and no serious safety signals have emerged at 12 weeks. That does not make NMN or NR a standard of care. The trials are small (N=10 to 40 in most cases), short (10 to 12 weeks), and often funded by supplement manufacturers.

The strongest case for use in adults over 65 combines clinical evidence with a plausible biological mechanism: a patient with documented muscle weakness, insulin resistance, or early metabolic syndrome who is already engaging in structured exercise may see incremental benefit from 250 to 500 mg NMN or NR per day. The evidence does not support use for cognitive decline prevention, cancer prevention, or life extension at current human data levels.

The Exercise Interaction

A 2023 Cell Metabolism study by Cartee and colleagues confirmed that NAD+ precursor supplementation and aerobic exercise activate partially overlapping but distinct mitochondrial pathways, suggesting additive effects. [16] Older adults who are sedentary and begin both exercise and NMN simultaneously cannot separate the effects, but both are net positives for this population.

Monitoring Recommendations

Baseline labs before starting NMN or NR in older adults should include fasting glucose, HbA1c, a comprehensive metabolic panel, and CBC. Liver enzymes should be rechecked at 12 weeks given the nicotinamide pathway's hepatic processing. No RCT has shown hepatotoxicity from NMN or NR, but standard practice for any supplement with hepatic metabolism in older adults warrants monitoring.